Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: Meta-regression and subgroup analysis

Breast Cancer Research and Treatment

Volumn 122, Issue 2, 2010, Pages 471-481

  Chen, Yun ^b   Pei, Jianping ^a  

^a Jiangsu Provincial Architectural Design and Research Institute   (China)

^b NONE

Author keywords

Bayesian meta regression; Breast cancer; CYP17; Polymorphism; Subgroup meta analysis.

Indexed keywords

CYTOCHROME P450 17; CYTOSINE; ORAL CONTRACEPTIVE AGENT; THYMINE; STEROID 17ALPHA MONOOXYGENASE;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BAYES THEOREM; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CASE CONTROL STUDY; DNA POLYMORPHISM; ETHNICITY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; HORMONE SUBSTITUTION; HUMAN; MENARCHE; MENOPAUSE; ORAL CONTRACEPTION; PARITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIMULATION; TRANSLATION INITIATION; ADULT; AGE; AGED; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; MIDDLE AGED; PHENOTYPE; POSTMENOPAUSE; PREMENOPAUSE; RISK; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BAYES THEOREM; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PREMENOPAUSE; RISK ASSESSMENT; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 77955656089     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0690-9     Document Type: Article

References (65)

1. Kristensen VN, Borresen-Dale AL (2000) Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 462:323-333.
2. Thompson PA, Ambrosone C (2000) Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 27:125-134.
3. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689.
4. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR et al (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomark Prev 8:741-747.
5. Bennett IC, Gattas M, Teh BT (1999) The genetic basis of breast cancer and its clinical implications. Aust N Z J Surg 69:95-105.
6. Johnson-Thompson MC, Guthrie J (2000) Ongoing research to identify environmental risk factors in breast carcinoma. Cancer 88:1224-1229.
7. Picado-Leonard J, Miller WL (1987) Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17, 20 lyase): similarity with the gene for P450c21. DNA 6:439-448. (Pubitemid 18085844)
8. Miller WL (1998) Early steps in androgen biosynthesis: from cholesterol to DHEA. Baillieres Clin Endocrinol Metab 12:67-81.
9. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P et al (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3:1873-1876.
10. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57:1063-1065.
11. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE (1998) Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58:585-587.
12. Dunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL et al (1998) No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 77:2045-2047.
13. Helzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, Bell DA (1998) Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomark Prev 7:945-949.
14. Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, Wolff MS (1998) CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomark Prev 7:941-944.
15. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE et al (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59:1015-1020.
16. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59:4870-4875.
17. Hamajima N, Iwata H, Obata Y, Matsuo K, Mizutani M, Iwase T et al (2000) No association of the 50 promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res 91:880-885.
18. Kuligina ES, Togo AV, Suspitsin EN, Grigoriev MY, Pozharisskiy KM, Chagunava OL et al (2000) CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Lett 156:45-50.
19. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S et al (2000) Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomark Prev 9:1343-1348.
20. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE (2001) Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61:785-789.
21. Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S et al (2003) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 5:R45-R51.
22. Gudmundsdottir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE (2003) CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer 88:933-936.
23. Wu AH, Seow A, Arakawa K, Van Den Berg D, Lee HP, Yu MC (2003) HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 104: 450-457.
24. Chacko P, Rajan B, Mathew BS, Joseph T, Pillai MR (2004) CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer. Breast Cancer 11:380-388.
25. Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G et al (2004) Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 101:264-269.
26. Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL et al (2005) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Res 7:R513-R521.
27. Shin MH, Lee KM, Yang JH, Nam SJ, Kim JW, Yoo KY et al (2005) Genetic polymorphism of CYP17 and breast cancer risk in Korean women. Exp Mol Med 37:11-17.
28. Han DF, Zhou X, Hu MB, Xie W, Mao ZF, Chen DE et al (2005) Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J 118:1507-1516.
29. Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil RS, Sharma PC, Saxena S (2007) CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. J Hum Genet 52:159-165.
30. Chen Y, Gammon MD, Teitelbaum SL, Britton JA, Terry MB, Shantakumar S et al (2008) Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis 29:766-771.
31. Samson M, Rama R, Swaminathan R, Sridevi V, Nancy KN, Rajkumar T (2009) CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women. Asian Pac J Cancer Prev 10:111-114.
32. Zhang L, Gu L, Qian B, Hao X, Zhang W, Wei Q, Chen K (2009) Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat 114:327-338.
33. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomark Prev 8:843-854.
34. Ye Z, Parry JM (2002) The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17:119-126.
35. Feigelson HS, McKean-Cowdin R, Henderson BE (2002) Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17:445-446 (author reply 7-8).
36. Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR et al (2000) CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 92: 1674-1681.
37. Bergman-Jungestrom M, Gentile M, Lundin AC, Wingren S (1999) Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 84:350-353. (Pubitemid 29337118)
38. Chen Y, Pei J (2009) An assessment of a TNF polymorphic marker for the risk of HCV infection: meta-analysis and a new clinical study design. Infect Genet Evol 9:1356-1363.
39. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI (2009) Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 63:1426-1434.
40. Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crino L et al (2009) CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer 9:115.
41. Attia J, Thakkinstian A, D'Este C (2003) Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 56:297-303.
42. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2005) The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 34:1319-1328.
43. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558.
44. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
45. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
46. Carlin BP, Galfand AE, Smith AFM (1992) Hierarchical Bayesian analysis of changepoint problems. Appl Stat 41: 389-408.
47. Breslow NE, Clayton DG (1993) Approximate inference in generalized linear mixed models. J Am Stat Assoc 88:9-25.
48. Boston RC, Sumner AE (2003) STATA: a statistical analysis system for examining biomedical data. Adv Exp Med Biol 537:353-369.
49. DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105-114.
50. Spiegelhalter D, Thomas A, Best N, Lunn D (2003) Winbugs user manual. MRC Biostatistics Unit, Cambridge.
51. Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, Chang-Claude J (2006) CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J Nutr 136:1596-1603.
52. Verla-Tebit E, Wang-Gohrke S, Chang-Claude J (2005) CYP17 50-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Breast Cancer Res 7:R455-R464.
53. Einarsdottir K, Rylander-Rudqvist T, Humphreys K, Ahlberg S, Jonasdottir G, Weiderpass E et al (2005) CYP17 gene polymorphism in relation to breast cancer risk: a case-control study. Breast Cancer Res 7:R890-R896.
54. Young IE, Kurian KM, Annink C, Kunkler IH, Anderson VA, Cohen BB et al (1999) A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 81:141-143.
55. Spicer DV, Pike MC (1994) Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr 16:139-147.
56. Salanti G, Sanderson S, Higgins JP (2005) Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7:13-20.
57. Nam IS, Mengersen K, Garthwaite P (2003) Multivariate metaanalysis. Stat Med 22:2309-2333.
58. van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and metaregression. Stat Med 21:589-624.
59. Schmid CH (2001) Using Bayesian inference to perform metaanalysis. Eval Health Prof 24:165-189.
60. Tran BN, Nguyen ND, Eisman JA, Nguyen TV (2008) Association between LRP5 polymorphism and bone mineral density: a Bayesian meta-analysis. BMC Med Genet 9:55.
61. Bernstein L, Pike MC, Ross RK, Henderson BE (1991) Age at menarche and estrogen concentrations of adult women. Cancer Causes Control 2:221-225.
62. Goodman MT, McDuffie K, Guo C, Terada K, Donlon TA (2001) CYP17 genotype and ovarian cancer: a null case-control study. Cancer Epidemiol Biomark Prev 10:563-564.
63. Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomark Prev 14:815-820.
64. Butt S, Borgquist S, Anagnostaki L, Landberg G, Manjer J (2009) Parity and age at first childbirth in relation to the risk of different breast cancer subgroups. Int J Cancer 125:1926-1934.
65. Yip CH (2009) Breast cancer in Asia. Methods Mol Biol 471: 51-64.